GKOS NYSE
Glaukos Corporation
1W: -2.1%
1M: +14.4%
3M: +15.7%
YTD: +25.6%
1Y: +42.7%
3Y: +132.2%
5Y: +86.1%
$120.23
-18.80 (-13.52%)
Weekly Expected Move ±12.1%
$109
$127
$144
$161
$179
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (24h)
2
Hourly Sentiment (24h)
-0.10
Neutral
4 bullish
0 neutral
5 bearish
Articles (7d)
9
Daily Sentiment (7 Days)
Articles (84)
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Glaukos Plunges 11.2% After BTIG Maintains Buy - AlphaStreet
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday
Glaukos Insider Makes Major Move With High-Value Stock Sale - TipRanks
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos Corporation (GKOS) Stock Analysis: Strong Buy Ratings Signal Promising Upside in the Medical Device Arena - DirectorsTalk Interviews
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding - Stock Titan
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares - Stock Titan
Insider Sale: Director at $GKOS Sells 5,000 Shares - Quiver Quantitative
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
How to watch Glaukos at four upcoming investor conferences - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations
Glaukos Stock Leaps 23% In One Day, Now Is Not The Time To Buy The Stock - Trefis
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out
12 Health Care Stocks Moving In Thursday's Intraday Session
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Glaukos Q1 Earnings Call Highlights
Glaukos Corp (GKOS) Q1 2026 Earnings Call Highlights: Record Sales Surge and Raised Guidance
Glaukos outlines $620M-$635M 2026 net sales outlook following Q1 outperformance
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Glaukos Corporation Q1 2026 Earnings Call Summary
Glaukos Corporation Q1 2026 Earnings Call Summary
Glaukos (GKOS) Q1 2026 Earnings Transcript
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
12 Health Care Stocks Moving In Wednesday's After-Market Session
Glaukos Non-GAAP EPS of -$0.18 beats by $0.10, revenue of $150.6M beats by $13.6M
Glaukos Announces First Quarter 2026 Financial Results
Here are the major earnings after the close Wednesday
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Is ISRG's International Weakness a Temporary Drag or Structural Risk?
Earnings Scheduled For April 29, 2026
Eye-device maker Glaukos lifts outlook after $150.6M quarter - Stock Titan
April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value
3 Stocks That Might Be Undervalued By Up To 32.8%
3 Stocks That Might Be Undervalued By Up To 48.3% Offering A Possible Discount
LSI Industries And 2 Other Stocks That May Be Priced Below Estimated Value
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
New CMS billing code could widen access to Glaukos eye treatment - Stock Titan
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock
Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?
Alliancebernstein L.P. Has $141.37 Million Holdings in Glaukos Corporation $GKOS
GKOS Stock Falls -20% In 9-day Spree On Earnings Shock And Asset Impairment - Trefis
Capital International Investors Buys 264,971 Shares of Glaukos Corporation $GKOS
Atika Capital Management LLC Has $17.32 Million Position in Glaukos Corporation $GKOS
What is Zacks Research’s Forecast for Glaukos Q1 Earnings?
Citigroup Inc. Sells 34,689 Shares of Glaukos Corporation $GKOS
Glaukos Corporation $GKOS Shares Purchased by AustralianSuper Pty Ltd
Glaukos Stock Jumps 13% After Q4 Beat: Here’s What Its 2026 Guidance Signals - TIKR.com
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
Comparing Glaukos (NYSE:GKOS) & Inogen (NASDAQ:INGN)
Glaukos (GKOS) Expected to Beat Earnings Estimates: Should You Buy?
Principal Financial Group Inc. Reduces Stock Position in Glaukos Corporation $GKOS
Director Sells GKOS 15,000 Shares for $1.9 Million
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos (NYSE:GKOS) Stock Price Up 6% Following Analyst Upgrade
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
Insider Sale: CHAIRMAN & CEO of $GKOS Sells 186,945 Shares | GKOS Stock News - Quiver Quantitative
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
Glaukos Corporation (GKOS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos Corporation $GKOS Shares Sold by Texas Permanent School Fund Corp
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
Glaukos Corporation (GKOS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ameritas Investment Partners Inc. Has $590,000 Holdings in Glaukos Corporation $GKOS
Here's Why You Should Retain Glaukos Stock in Your Portfolio
Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?
Creative Planning Has $1.90 Million Stock Holdings in Glaukos Corporation $GKOS